Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced record revenues in December and the 4th quarter. 2021 revenue growth over 2020 was dramatic.
“Sepsis continues to be a critical challenge for hospitals, and helping them reduce their contaminated blood cultures is as important as ever,” said Bob Rogers, CEO of Kurin, Inc. “Kurin is simple to use and does not require a change in practice, helping hospitals address the critical issue of blood culture contamination.”
“The pandemic continues to present challenges to everyone and I give credit to our team for their persistence and diligence in helping hospitals when they need it most,” said Mr. Rogers. “We continue to build upon the company’s strong financial position.”
Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.
About Kurin, Inc.
Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.